Document is current
Any future updates will be listed below
-
Authors
Höfer, Stefanie https://orcid.org/0009-0006-0489-6854
Frasch, Larissa https://orcid.org/0009-0008-1529-7341
Brajkovic, Sarah
Putzker, Kerstin https://orcid.org/0000-0001-8375-5908
Lewis, Joe
Schürmann, Hendrik https://orcid.org/0000-0002-8195-4396
Leone, Valentina
Sakhteman, Amirhossein
The, Matthew https://orcid.org/0000-0002-5401-5553
Bayer, Florian P
Müller, Julian https://orcid.org/0000-0003-4108-7926
Hamood, Firas
Siveke, Jens T https://orcid.org/0000-0002-8772-4778
Reichert, Maximilian https://orcid.org/0000-0002-8611-5639
Kuster, Bernhard https://orcid.org/0000-0002-9094-1677
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (329628492)
Deutsche Forschungsgemeinschaft (FU 356/12-2)
Bundesministerium für Bildung und Forschung (031L0305A)
Bundesministerium für Bildung und Forschung (01KD2206A/SATURN3)
EC | ERC | HORIZON EUROPE European Research Council (833710)
- License Information
-
More Information
Article History
Received: 2 April 2024
Revised: 22 December 2024
Accepted: 3 January 2025
First Online: 21 January 2025
Disclosure and competing interests statement
: BK is co-founder and shareholder of OmicScouts and MSAID. He has no operational role in either company. JTS receives honoraria as consultant or for continuing medical education presentations from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Immunocore, MSD Sharp Dohme, Novartis, Roche/Genentech, and Servier. His institution receives research funding from Abalos Therapeutics, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eisbach Bio, and Roche/Genentech; he holds ownership in FAPI Holding (< 3%); all outside the submitted work. HS received travel support from Servier, with no financial benefit and outside the submitted work. The remaining authors declare no competing interests.
